AlzeCure Pharma Future Growth
Future criteria checks 2/6
AlzeCure Pharma's earnings are forecast to decline at 32.5% per annum while its annual revenue is expected to grow at 39.5% per year.
Key information
-32.5%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 73.2% |
| Revenue growth rate | 39.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth
Dec 02
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth
Jul 20Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?
Oct 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jan 03Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jul 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Mar 28Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares
Feb 03We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate
Dec 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -71 | N/A | N/A | 1 |
| 12/31/2025 | 44 | -17 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -35 | N/A | N/A | 1 |
| 9/30/2024 | N/A | -36 | -36 | -36 | N/A |
| 6/30/2024 | N/A | -36 | -35 | -35 | N/A |
| 3/31/2024 | N/A | -37 | -35 | -35 | N/A |
| 12/31/2023 | N/A | -37 | 3 | 3 | N/A |
| 9/30/2023 | N/A | -38 | -40 | -40 | N/A |
| 6/30/2023 | N/A | -42 | -47 | -47 | N/A |
| 3/31/2023 | N/A | -53 | -14 | -14 | N/A |
| 12/31/2022 | N/A | -56 | -100 | -100 | N/A |
| 9/30/2022 | N/A | -68 | -70 | -70 | N/A |
| 6/30/2022 | N/A | -73 | -70 | -70 | N/A |
| 3/31/2022 | N/A | -67 | -110 | -110 | N/A |
| 12/31/2021 | N/A | -78 | -71 | -71 | N/A |
| 9/30/2021 | N/A | -73 | -70 | -70 | N/A |
| 6/30/2021 | N/A | -78 | -75 | -75 | N/A |
| 3/31/2021 | N/A | -81 | -78 | -78 | N/A |
| 12/31/2020 | N/A | -71 | -70 | -70 | N/A |
| 9/30/2020 | N/A | -69 | -64 | -63 | N/A |
| 6/30/2020 | N/A | -61 | -57 | -56 | N/A |
| 3/31/2020 | N/A | -53 | -50 | -49 | N/A |
| 12/31/2019 | N/A | -51 | -52 | -50 | N/A |
| 9/30/2019 | N/A | -48 | -50 | -49 | N/A |
| 6/30/2019 | -2 | -40 | -44 | -42 | N/A |
| 3/31/2019 | -1 | -38 | -40 | -39 | N/A |
| 12/31/2018 | N/A | -36 | -37 | -36 | N/A |
| 9/30/2018 | 1 | -28 | -30 | -29 | N/A |
| 12/31/2017 | 1 | -10 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALZCUR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALZCUR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALZCUR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALZCUR's revenue (39.5% per year) is forecast to grow faster than the Swedish market (-0.04% per year).
High Growth Revenue: ALZCUR's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALZCUR's Return on Equity is forecast to be high in 3 years time